



|   |   |    |                          |                        |                 |
|---|---|----|--------------------------|------------------------|-----------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |                 |
|   |   |    | Application Number       | 10/690,495-Conf. #8657 |                 |
|   |   |    | Filing Date              | October 21, 2003       |                 |
|   |   |    | First Named Inventor     | Arthur M. Krieg        |                 |
|   |   |    | Art Unit                 | 1645                   |                 |
|   |   |    | Examiner Name            | N. Archie              |                 |
| Sheet   | 1 | of | 2                        | Attorney Docket Number | C1039.70083US00 |

| U.S. PATENT DOCUMENTS |                          |  |                                |  |   |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
| /NA/                  |                          | 6,030,954*                               |                                | Wu et al.  |   |
| /NA/                  |                          | 6,620,805*                               |                                | Takle et al.                                       |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |   |   |                |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |   |   |                |
|                          |                       |   |                                |   |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                          |   |  |                    | T <sup>2</sup> |
|---------------------------------|--------------------------|---|--|--------------------|----------------|
| Examiner<br>Initials            | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |                    |                |
| /NA/                            |                          | BENNETT, C. F., 1995, "Intracellular Delivery of Oligonucleotides with Cationic Liposomes,"<br>Delivery Strategies for Antisense Oligonucleotide Therapeutics, Akthar, Ed.: 223-32 (Abstract)   |  |                    |                |
|                                 |                          | KRIEG, A., 2007, "Antiinfective Applications of Toll-like Receptor 9 Agonists," Proc Am Thorac<br>Soc Vol. 4: 289-294   |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on<br>interference estoppel). (Electronically filed, unsigned).  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on<br>inadequate written description and/or enablement). (Electronically filed, unsigned). June 18,<br>2007.   |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104<br>and 105). (Electronically filed, unsigned). July 25, 2007.  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior<br>art). (Electronically filed, unsigned). June 18, 2007.  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35<br>U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.   |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-<br>in-Fact). (Electronically filed, unsigned). June 18, 2007.  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526.. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior<br>Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as<br>Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.   |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz<br>Parent Application) (Electronically filed, unsigned) July 25, 2007.  |  |                    |                |
|                                 |                          | Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim<br>58) (Electronically filed, unsigned) July 25, 2007.  |  |                    |                |
| Examiner<br>Signature           | /Nina Archie/            |   |  | Date<br>Considered | 12/18/2007     |

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/690,495-Conf. #8657 |
|  |   |    |   | Filing Date              | October 21, 2003       |
|  |   |    |   | First Named Inventor     | Arthur M. Krieg        |
|  |   |    |   | Art Unit                 | 1645                   |
|  |   |    |   | Examiner Name            | N. Archie              |
| Sheet  | 2 | of | 2 | Attorney Docket Number   | C1039.70083US00        |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |  |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |  |
| /NA/                            |                       | Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.   |                |  |
|                                 |                       | Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.  |                |  |
|                                 |                       | PRESS RELEASE, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".  |                |  |
|                                 |                       | PRESS RELEASE, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".  |                |  |
|                                 |                       | YAMAMOTO et al., 1994, "Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity," Microbiol. Immunol. 38(10): 831-836.                       |                |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |               |                 |            |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Nina Archie/ | Date Considered | 12/18/2007 |
|--------------------|---------------|-----------------|------------|

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

Sheet 1 of 1

## U.S. PATENT DOCUMENTS

| Examiner's<br>Initials # | Cite<br>No. | U.S. Patent Document |              | Name of Patentee or Applicant of Cited<br>Document | Date of Publication or Issue<br>of Cited Document<br>MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
|                          |             | Number               | Kind<br>Code |  |   |
| /NA/                     |             | 2007-0224210         | A1           | Krieg et al.                                       | 09-27-2007  |
| /NA/                     |             | 2007-0232622         | A1           | Lipford et al.                                     | 10-04-2007  |
|                          |             |                      |              |  |   |

## FOREIGN PATENT DOCUMENTS

| Examiner's<br>Initials # | Cite<br>No. | Foreign Patent Document |        |              | Name of Patentee or Applicant of Cited<br>Document | Date of<br>Publication of<br>Cited Document<br>MM-DD-YYYY | Translation<br>(Y/N) |
|--------------------------|-------------|-------------------------|--------|--------------|--|---|----------------------|
|                          |             | Office/<br>Country      | Number | Kind<br>Code |  |   |                      |
|                          |             |                         |        |              |  |   |                      |
|                          |             |                         |        |              |  |   |                      |
|                          |             |                         |        |              |  |   |                      |

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's<br>Initials # | Cite<br>No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item<br>(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher,<br>city and/or country where published. | Translation<br>(Y/N) |
|--------------------------|------------|---|----------------------|
| /NA/                     |            | Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007  |                      |
|                          |            | Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007  |                      |


EXAMINER:

/Nina Archie/

DATE CONSIDERED: 12/18/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]



FORM PTO/A and B (Modified PTO/SB/08)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

1

of

5

12/18/2007

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

**U.S. PATENT DOCUMENTS**

| Examiner's<br>Initials # | Cite<br>No. | U.S. Patent Document |              | Name of Patentee or Applicant of Cited<br>Document | Date of Publication or Issue<br>of Cited Document<br>MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
|                          |             | Number               | Kind<br>Code |  |   |
| /NA/                     |             | 5,023,243            |              | Tullis   | 06-11-1991  |
|                          |             | 5,087,617            |              | Smith  | 02-11-1992  |
|                          |             | 5,248,670            |              | Draper et al.                                      | 09-28-1993  |
|                          |             | 5,457,189            |              | Crooke et al.                                      | 10-10-1995  |
|                          |             | 5,514,577            |              | Draper et al.                                      | 05-07-1996  |
|                          |             | 5,567,604            |              | Rando et al.                                       | 10-22-1996  |
|                          |             | 5,576,302            |              | Cook et al.  | 11-19-1996  |
|                          |             | 5,594,122            |              | Friesen  | 01-14-1997  |
|                          |             | 5,658,891            |              | Draper et al.                                      | 08-19-1997  |
|                          |             | 5,665,580            |              | Crooke et al.                                      | 09-09-1997  |
|                          |             | 5,681,944            |              | Crooke et al.                                      | 10-28-1997  |
|                          |             | 5,728,518            |              | Carmichael   | 03-17-1998  |
|                          |             | 5,756,097            |              | Landucci et al.                                    | 05-26-1998  |
|                          |             | 5,780,448            |              | Davis  | 07-14-1998  |
|                          |             | 5,837,243            |              | Deo et al.   | 11-17-1998  |
|                          |             | 5,843,770            |              | Ill et al.   | 12-01-1998  |
|                          |             | 5,854,418            |              | Chang et al.                                       | 12-29-1998  |
|                          |             | 5,858,987            |              | Beer-Romero et al.                                 | 01-12-1999  |
|                          |             | 5,877,309            |              | McKay et al.                                       | 03-02-1999  |
|                          |             | 5,955,059            |              | Gilchrest et al.                                   | 09-21-1999  |
|                          |             | 5,985,662            |              | Anderson et al.                                    | 11-16-1999  |
|                          |             | 5,997,858            |              | Tovey et al.                                       | 12-07-1999  |
|                          |             | 6,107,062            |              | Hu et al.  | 08-22-2000  |
|                          |             | 6,114,167            |              | Symonds et al.                                     | 09-05-2000  |
|                          |             | 6,184,369            | B1           | Rando et al.                                       | 02-06-2001  |
|                          |             | 6,426,334            | B1           | Agrawal et al.                                     | 07-30-2002  |

**FOREIGN PATENT DOCUMENTS**

| Examiner's<br>Initials # | Cite<br>No. | Foreign Patent Document |          |              | Name of Patentee or Applicant of Cited<br>Document               | Date of<br>Publication of<br>Cited Document<br>MM-DD-YYYY | Translation<br>(Y/N) |
|--------------------------|-------------|-------------------------|----------|--------------|--|---|----------------------|
|                          |             | Office/<br>Country      | Number   | Kind<br>Code |  |   |                      |
| /NA/                     |             | WO                      | 95/17507 | A1           | Biagnostik Gesellschaft Für<br>Biomolekulare Diagnostik MBH [DE] | 06-29-1995  |                      |

EXAMINER:

/Nina Archie/

DATE CONSIDERED:

12/18/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

Sheet

2

of

5

|      |  |    |          |    |   |            |  |
|------|--|----|----------|----|---|------------|--|
| /NA/ |  | WO | 96/02560 | A1 | University of North Carolina at Chapel Hill | 02-01-1996 |  |
| ↓    |  | WO | 97/28259 | A1 | The Regents of the University of California | 08-07-1997 |  |
|      |  | WO | 98/32462 | A1 | Wagner et al.                               | 07-30-1998 |  |
|      |  | WO | 99/33488 | A2 | SmithKline Beecham Biologicals S.A.         | 07-08-1999 |  |

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | Translation (Y/N) |
|-----------------------|---------|---|-------------------|
| /NA/                  |         | [No Author Listed] CpG 7909: PF 3512676, PF-3512676. Drugs R D. 2006;7(5):312-6.  |                   |
| ↓                     |         | BAYEVER et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993 Winter;3(4):383-90.   |                   |
|                       |         | BRANDA et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med. 1996 Sep;128(3):329-38.  |                   |
|                       |         | BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.  |                   |
|                       |         | BRIGNOLE et al., Immune cell-mediated antitumor activities of GD2-targeted liposomal c-mycb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst. 2004 Aug 4;96(15):1171-80.  |                   |
|                       |         | COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.   |                   |
|                       |         | COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.   |                   |
|                       |         | DASS et al., Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol. 2002 Apr;128(4):177-81. Abstract Only.  |                   |
|                       |         | GEISSLER et al., Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997 Feb 1;158(3):1231-7.  |                   |
|                       |         | HIGAKI et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. Immunol Cell Biol. 1994 Jun;72(3):205-14.  |                   |
|                       |         | HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol. 1997 Jul;71(7):5528-39.   |                   |
|                       |         | IVERSEN et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994 Spring;4(1):43-52.   |                   |
| ↓                     |         | JACOBSON et al., Early viral response and on treatment response to CpG 10101 (ACTILON™), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 57 <sup>th</sup> Annual Meeting of American Association for the Study of the Liver Diseases (AASLD). 2006 Oct 30, Boston, Massachusetts; Presented Abstract #96. |                   |

EXAMINER:

/Nina Archie/

DATE CONSIDERED:

12/18/2007

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

Sheet

3

of

5

|      |  |   |  |
|------|--|---|--|
| /NA/ |  | JOHNSON et al., Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance. 1987: 291-301.   |  |
|      |  | KNIPE et al., eds., Fields' Virology. 2001;1:1004-16.   |  |
|      |  | KNIPE et al., eds., Fields' Virology. 2001;1:1564.  |  |
|      |  | KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.   |  |
|      |  | KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.   |  |
|      |  | KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.  |  |
|      |  | KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.   |  |
|      |  | KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.  |  |
|      |  | KRIEG et al., Rescue of B cells from apoptosis by immune stimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):55-61.  |  |
|      |  | KRIEG et al., Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul;4(3):289-94.  |  |
|      |  | KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.  |  |
|      |  | LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.                         |  |
|      |  | LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.  |  |
|      |  | LI et al., Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine. 2001 Oct 12;20(1-2):148-57.   |  |
|      |  | LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.   |  |
|      |  | LOKE et al., Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol. 1988;141:282-9. |  |
|      |  | MacFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology. 1997 Aug;91(4):586-93.  |  |
|      |  | MAJOR et al. Chapter 34 Hepatitis C Viruses. in Fields' Virology. 2001;1:1127-61  |  |
| ✓    |  | MALTESE et al., Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity. Nucleic Acids Res. 1995 Apr 11;23(7):1146-51.   |  |

EXAMINER:

/Nina Archie/

DATE CONSIDERED:

12/18/2007

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

Sheet

4

of

5

|      |  |  |              |
|------|--|--|--------------|
| /NA/ |  | MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by <i>Klebsiella pneumoniae</i> ] <i>Gac Med Mex.</i> 1995 Jan-Feb;131(1):14-22. Spanish.   | Y – Abstract |
|      |  | MANEGOLD et al., Addition of PF-3512676 (CpG 7909) to a taxane/platinum regimen for first-line treatment of unresectable non-small cell lung cancer (NSCLC) improves objective response—Phase II clinical trial. Pfizer Poster. 2005. Abstract 1131.   |              |
|      |  | MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. <i>Proc Natl Acad Sci U S A.</i> 1989 Jun;86(11):4244-8.  |              |
|      |  | McHUTCHISON et al., Early viral response to CpG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 41 <sup>st</sup> Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 26-30, Vienna, Austria; Submitted Abstract. |              |
|      |  | McHUTCHISON et al., Final results of a multi-center phase 1B, randomized, placebo-controlled, dose-escalation trial of CpG 10101 in patients with chronic hepatitis C virus. 41 <sup>st</sup> Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 30, Vienna, Austria; Presented Abstract #111.             |              |
|      |  | McHUTCHISON et al., Early clinical results with CpG 10101, a new investigational antiviral TLR9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus. 12 <sup>th</sup> International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). 2006 July 3, Paris, France; Presented Abstract #O105. |              |
|      |  | MUHLHAUSER et al., VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. <i>Circ Res.</i> 1995 Dec;77(6):1077-86.   |              |
|      |  | OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. <i>Int J Immunotherapy.</i> 1986;11(4):259-65.  |              |
|      |  | PERLAKY et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. <i>Anticancer Drug Des.</i> 1993 Feb;8(1):3-14.   |              |
|      |  | PISETSKY et al., Immunological properties of bacterial DNA. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:152-63.   |              |
|      |  | PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci.</i> 1994;54(2):101-7.   |              |
|      |  | RATAJCZAK et al., In vivo treatment of human leukemia in a scid mouse model with c-myc antisense oligodeoxynucleotides. <i>Proc Natl Acad Sci U S A.</i> 1992 Dec 15;89(24):11823-7.   |              |
|      |  | RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.   |              |
|      |  | RYNKIEWICZ et al., Marked enhancement of antibody response to anthrax vaccine adsorbed with CPG 7909 in healthy volunteers. 45 <sup>th</sup> Intersci. Conf. Antimicrob. Agents Chemother. 2005 Sep. 21-24; New Orleans, Louisiana. Meeting Poster.  |              |
| ✓    |  | SEDEGAH et al., Interleukin 12 induction of interferon gamma-dependent protection against malaria. <i>Proc Natl Acad Sci U S A.</i> 1994 Oct 25;91(22):10700-2.  |              |

EXAMINER:

/Nina Archie/

DATE CONSIDERED:

12/18/2007

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/690,495

ATTY. DOCKET NO.: C1039.70083US00

FILING DATE: October 21, 2003

CONFIRMATION NO.: 8657

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: N. Archie

Sheet

5

of

5

|      |   |     |
|------|---|-----|
| /NA/ | SEMPLE et al., Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2005 Mar;312(3):1020-6. Epub 2004 Nov 3.                           |     |
|      | SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4.  |     |
|      | STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.   |     |
|      | SUZUKI et al., Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 2004 Dec 1;64(23):8754-60.   |     |
|      | TAKATSUKI et al., Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990 May 15;50(10):2885-90.   |     |
|      | TAM et al., Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides. Future Lipidology. 2006 Feb; 1(1): 35-46   |     |
|      | TOKUNAGA, Response of the organism to DNA - With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese.   | Yes |
|      | WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14.                                 |     |
|      | WEINER et al., Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotypic antibody and is synergistic with GMCSF. Blood. 1996 Nov 15;88(10):Suppl. 1 pt. 1. Abstract #348. |     |
|      | WOOLDRIDGE et al., Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity in vitro and in vivo. Proc Am Assoc Cancer Res. 1996 Mar;37(3253):477.   |     |
|      | WOOLDRIDGE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15;89(8):2994-8.  |     |
|      | YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese.  | Yes |
|      | Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive Motion 6) (Electronically filed, unsigned) September 10, 2007.   |     |
|      | Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070, 2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007.  |     |
|      | Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5) October 25, 2007.   |     |
|      | Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19, 2007.   |     |
|      | Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25, 2007.   |     |
|      | Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007.  |     |
|      | Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.  |     |

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:

/Nina Archie/

DATE CONSIDERED:

12/18/2007

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.